Structure Therapeutics (GPCR) is expanding its obesity pipeline with ACCG-2671, a once-daily small molecule amylin agonist, setting the stage for a potential monotherapy and a dual combination therapy with GSBR-1290, H.C. Wainwright tells investors in a research note. The preclinical data showing comparable efficacy to cagrilintide is “impressive,” and Merck’s (MRK) “risky” deal does not perturb the firm’s thesis that small molecule platform and the pipeline is robust and differentiated, H.C. Wainwright adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GPCR:
- Structure Therapeutics Advances Obesity Treatment Candidate
- Jefferies Predicts Up to ~1000% Surge for These 2 ‘Strong Buy’ Stocks
- Structure Therapeutics price target raised to $91 from $86 at JMP Securities
- Structure Therapeutics initiated with a Buy at H.C. Wainwright
- Structure Therapeutics Reports Strong Q3 2024 Results